ACAD
ACAD
Positions held
Your positionsACAD isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · RBC Trims Price Target on ACADIA Pharmaceuticals to $36 From $37, Keeps Outperform Rating
2026-10-06 · Acadia Pharmaceuticals (ACAD) Secures Patent And Phase 2 Progress, Is It 38% Below Fair Value?
2026-09-29 · Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
2026-09-28 · Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent
2026-09-28 · 3 Stocks Put Traders Are Targeting Today: AMTX, ACAD, REZI
2026-09-27 · Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop
2026-09-25 · Acadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says
2026-09-25 · ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets
2026-09-25 · ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal
2026-09-25 · Acadia chugs on with Alzheimer’s psychosis programme despite Phase II miss
2026-09-25 · Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
Price (daily)
Full chart · RSI · MACD · patterns